Analyst Price Targets — QDEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 7, 2026 12:15 pm | Lu Li | UBS | $12.00 | $10.74 | TheFly | QuidelOrtho price target lowered to $12 from $17 at UBS |
| May 7, 2026 9:10 am | Tycho Peterson | Jefferies | $12.50 | $10.96 | TheFly | QuidelOrtho downgraded to Hold from Buy at Jefferies |
| April 10, 2026 11:35 am | — | UBS | $17.00 | $13.94 | TheFly | QuidelOrtho price target lowered to $17 from $30 at UBS |
| February 12, 2026 2:29 pm | — | UBS | $30.00 | $23.19 | TheFly | QuidelOrtho price target lowered to $30 from $35 at UBS |
| January 21, 2026 11:20 am | — | UBS | $35.00 | $32.73 | TheFly | QuidelOrtho price target raised to $35 from $31 at UBS |
| September 19, 2024 8:37 am | Lu Li | UBS | $50.00 | $46.23 | TheFly | QuidelOrtho assumed with Neutral from Sell at UBS |
| September 5, 2024 7:26 am | Bill Bonello | Craig-Hallum | $57.00 | $42.93 | StreetInsider | Craig-Hallum Upgrades Quidel Corp. (QDEL) to Buy |
| August 15, 2023 3:08 pm | Andrew Cooper | Raymond James | $110.00 | $74.47 | Benzinga | Analyst Is Frustrated By QuidelOrtho's Reduction In Guidance - Here's Why |
| December 12, 2022 7:28 am | — | Citigroup | $125.00 | $92.30 | Benzinga | Citigroup Upgrades QuidelOrtho to Buy, Raises Price Target to $125 |
| December 7, 2022 4:43 am | — | RBC Capital | $125.00 | $92.19 | Benzinga | RBC Capital Initiates Coverage On QuidelOrtho with Outperform Rating, Announces Price Target of $125 |
Latest News for QDEL
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most…
QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QDEL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.